Allergan Inc. (AGN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Allergan (AGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Allergan fell 85 cents (-1%) to $84.56 on average volume. Throughout the day, 1.8 million shares of Allergan exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $84.50-$85.12 after having opened the day at $85.07 as compared to the previous trading day's close of $85.41. Other companies within the Drugs industry that declined today were: Catalyst Pharmaceutical Partners (CPRX), down 19.6%, Senesco Technologies (SNT), down 12%, Ampio Pharmaceuticals (AMPE), down 9.6%, and Skystar Bio-Pharmaceutical Company (SKBI), down 8.8%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $25.66 billion and is part of the health care sector. The company has a P/E ratio of 25, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are down 2.7% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Allergan a buy, one analyst rates it a sell, and eight rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

• You can view the full Allergan Ratings Report.

On the positive front, Peregrine Pharmaceuticals (PPHM), up 26.7%, Bacterin International Holdings (BONE), up 17.8%, Rexahn Pharmaceuticals (RNN), up 16%, and Opexa Therapeutics (OPXA), up 15.9%, were all gainers within the drugs industry with BioMarin Pharmaceuticals (BMRN) being today's featured drugs industry leader.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Allergan Inc. click any of the following:

• Allergan Inc. Stock Price

• Allergan Inc. Analyst Ratings

• Allergan Inc. Key Stats & Profile

• Allergan Inc. Earnings

• Allergan Inc. Ratio Comparison

• Allergan Inc. Growth Rates

• Allergan Inc. Balance Sheet

• Allergan Inc. Cash Flow

• Allergan Inc. Income Statement